Invitae is pleased to announce that we’ve updated five hereditary cancer panels to meet the NCCN Guidelines®.1,2
Based on the latest NCCN Guidelines,1 we’ve added the following genes to our offering:
The following panels have been updated accordingly:
National Comprehensive Cancer Network® (NCCN®) also recently updated their guidelines2 to include the consideration of genetic testing for BRCA1, BRCA2, ATM, PALB2, and FANCA for all castrate-resistant prostate cancers. A positive result in these genes may change medical management.
The Invitae Prostate Cancer Panel includes all NCCN-recommended genes.
Invitae’s reference guide offers more information about which prostate cancer patients should be considered for genetic testing and how results impact treatment decisions.
We look forward to further evolving our offering to ensure your patients get the testing they need.
*Analysis is limited to sequencing analysis.
1. Referenced with permission from the NCCN: Genetic/Familial High-Risk Assessment: Colorectal V3.2017. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed March 9, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org.
2. Referenced with permission from the NCCN: Prostate Cancer V2.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed March 9, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org.
3. Adam R et al. Am J Hum Genet. 2016;99:337-51.
4. Weren RD et al. Nat Genet. 2015;47:668-671.
5. Rivera B et al. N Engl J Med. 2015;373:1985-1986.
6. Broderick P et al. BMC Cancer. 2006;6:243.
7. Nieminen TT et al. Gastroenterol. 2014;147:595-598.e595.
The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.